New stomach cancer fight: triple attack before surgery
NCT ID NCT07408609
Summary
This study is testing if a three-part treatment is better than standard chemotherapy for people with a type of stomach or esophagus cancer that can be removed with surgery. Before surgery, patients will get either standard chemotherapy alone or chemotherapy plus low-dose radiation and an immunotherapy drug called tislelizumab. The goal is to see if the combination treatment shrinks the tumor more effectively and helps prevent the cancer from coming back.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.